When an HIV Scientific Breakthrough Isn't Enough
We should be celebrating its arrival.
Instead, aid groups and the countries most affected by HIV are reeling from the Trump administration's relentless attacks on the global health infrastructure. Instead of perfecting plans for a rollout of the medication, they are scrambling to ensure people with HIV have the drugs they need to survive.
Last year, I wrote about the stunning — or as one HIV expert described it, 'spine-chilling'— results from a large study of lenacapavir. None of the women and adolescents who were given the twice-yearly injection in the trial became infected with HIV. In a second study involving men who have sex with men, and transgender individuals who have sex with men, the treatment was 96% effective. Even better, Gilead is working on a newer version that could potentially offer protection for a year or more.
That's about as close to an HIV vaccine we're likely to get — at least for many years. It's also the world's best shot of achieving the goal of ending HIV by 2030.
For low- and middle-income countries that continue to face frustratingly stubborn infection rates, a twice-yearly drug could be a game-changer. Although existing treatments of daily pills do an excellent job at preventing infection, getting people to use them consistently has been difficult.
There is the stigma attached to the pills. Ensuring patients return for frequent testing and refills is also challenging — as is simply remembering to take them daily. Consider the typical day of a mom with a newborn and it's easy to understand how six months of protection could make a real difference in lowering HIV cases in women and infants.
Some experts have even suggested lenacapavir is our best chance of wiping out new infections in children.
That was before the Trump administration abruptly shut down USAID, the lead agency behind Pepfar. The global initiative to combat HIV/AIDS is credited with saving an estimated 26 million lives since its inception in 2003. Although the administration granted a limited waiver to allow some HIV services to continue, funding is significantly restrained.
As health workers grapple with fewer resources, their focus has shifted to people living with HIV. 'When the chips are down, you safeguard treatment because those people will die if they don't get their antiretroviral,' says Linda-Gail Bekker, director of the Desmund Tutu HIV Centre at the University of Cape Town. And yet, she said, 'prevention we know is an absolute cornerstone to bringing this epidemic under control.'
Because the situation is so dynamic, it's been difficult to capture what's happening on the ground. The best current model suggests the administration's actions could result in at least 70,000 additional new infections, and another 5,000 deaths in the next five years.
UCLA infectious disease epidemiologist Dvora Joseph Davey says that in 2024, the eight public health clinics in Cape Town — where she is based — saw three infants who were HIV-positive at birth. In the first five months of this year, they've already seen three babies born with the infection.
She knows there will be more. One pregnant woman with HIV recently came into the clinic and, at 37 weeks, her viral load was dauntingly high. She'd skipped picking up her last three-month supply of pills. The nurse she'd been seeing was let go as part of the funding cuts, and no one was available to do a blood draw at her last visit, Davey says.
If the people who, in theory, should still be benefiting from global aid are falling through the cracks, what hope do we have for prevention?
Prevention efforts have already been severely disrupted in some countries. Supply is responsible for some of the upheaval, but the more complicated problem is getting the drugs to the people who need them most. 'We need low-cost product and also a low-cost delivery mode,' says Carmen Pérez Casas, senior strategy lead at Unitaid, a global health initiative hosted by the World Health Organization. The situation for the latter 'has changed radically,' she says.
HIV prevention is not as simple as just handing out a prescription. It's first identifying those most at risk of infection, getting them tested to confirm they are negative, and offering counseling about their options. It's ensuring they return for more testing and the next dose of their medication. That requires a vast support network ranging from doctors and nurses to counselors, pharmacists, lab technicians, data scientists and more.
Pepfar supported all of that infrastructure. In South Africa, for example, cuts have resulted in lost jobs for some 8,000 health workers focused on HIV.
Aid groups are doing their best to ensure the breakthrough's promise is not entirely lost. Their first hurdle is bridging the gap to the arrival of low-cost generic lenacapavir, which isn't expected until sometime in 2027. (Gilead is allowing a handful of drug companies to make and sell generic forms of lenacapavir in the countries most heavily impacted by HIV.) Global health agencies are anxiously awaiting the company's price tag for those countries to understand how far their funding can be stretched.
Then they need to get the drug to patients. Experts tell me they've scaled back their expectations given the upheaval with Pepfar. The Trump administration's termination of National Institutes of Health grants to foreign countries has created additional hurdles. It's been particularly devastating in South Africa, where the NIH supported a significant chunk of research related to HIV. That means less money to conduct so-called implementation studies for lenacapavir, which are crucial for understanding how to improve the drug's use in the real world. One simple thing the Trump administration could do is free up funding for prevention. Pepfar continues to operate under a waiver that only allows PrEP money to be spent for those who are pregnant or breastfeeding.
Groundbreaking science alone won't end HIV. It must be paired with affordability and access. The Trump administration's callous cuts to global health efforts put all of those things at risk — including the promising future where HIV is brought to heel.
More From Bloomberg Opinion:
This column reflects the personal views of the author and does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.
Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News.
More stories like this are available on bloomberg.com/opinion
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
16 hours ago
- Time of India
Losing weight without even trying? Here's why that can be dangerous
Why Sudden Weight Loss Is Concerning Conditions Often Linked to Unintentional Weight Loss When to See a Doctor Losing more than 5% of your body weight in six months without trying Persistent fatigue or a noticeable loss of muscle Chronic digestive symptoms Sudden behavioral or mood changes In a culture that often equates thinness with health, rapid weight loss is frequently applauded without question. Compliments flow freely, even when the change is unintended. However, not every drop in weight is a positive development. In fact, unexplained or unintentional weight loss can often be one of the earliest and most overlooked signs of a serious underlying health to the Times of India, Medical experts define unintentional weight loss as the loss of more than 5% of one's body weight over six to twelve months without any effort to slim down. Unlike deliberate weight loss through diet or exercise, this type of reduction can signal chronic illness, hormonal imbalances, digestive disorders, or even your body begins to shed weight without an identifiable cause, it's often a sign that something internal is not functioning properly. This may include the inability to absorb nutrients, an overactive immune response, or a disease-accelerating example, hyperthyroidism is a condition where the thyroid gland produces excessive hormones, causing a spike in metabolic rate. Individuals with this condition may feel more energetic at first, often brushing off symptoms like insomnia, tremors, or an increased appetite. As per health experts, a simple thyroid panel (TSH, T3, T4) can help detect this condition particularly Type 1 and advanced Type 2, is another condition that can lead to unexpected weight loss. When the body is unable to process glucose efficiently, it begins to burn muscle and fat for energy. This results in muscle wasting and a range of other symptoms like fatigue, frequent urination, and blurred vision. A basic blood glucose test is usually sufficient to identify digestive disorders such as Crohn's disease, ulcerative colitis, celiac disease, or IBS can impair the body's ability to absorb essential nutrients. Symptoms like chronic diarrhea, abdominal discomfort, and bloating are common but often dismissed or misattributed to dietary choices or stress. According to gastroenterologists, persistent gastrointestinal issues warrant comprehensive testing, including endoscopy and stool infections and autoimmune conditions like HIV, lupus, tuberculosis, or rheumatoid arthritis can also lead to weight loss. These illnesses often manifest with vague symptoms—fatigue, low-grade fever, or joint pain—and are frequently mistaken for minor viral of the most serious culprits is cancer, particularly gastrointestinal, pancreatic, or lung types. In many cases, weight loss is among the earliest signs. Individuals may also notice a loss of appetite, fatigue, or anemia. Because these symptoms can be subtle, they are often overlooked until the disease health disorders, including depression and anxiety, can also cause weight changes. A lack of interest in food, disrupted sleep, and gastrointestinal complaints are commonly observed. These symptoms often go unrecognized due to the stigma surrounding mental health or the tendency to separate emotional well-being from physical health Healthcare professionals recommend paying close attention if you experience any of the following:Experts urge people to resist societal norms that glorify all forms of weight loss. While fitness transformations through diet and exercise are commendable, unintentional weight reduction should not be dismissed or celebrated. As seen in the story of one fitness coach who consciously dropped from 85 to 60 kilograms through planned changes, the key difference lies in intention and overall health.
Time of India
a day ago
- Time of India
States sue Trump, saying he is intimidating hospitals over gender-affirming care for youth
Seventeen Democratic officials accused President Donald Trump 's administration of unlawfully intimidating health care providers into stopping gender-affirming care for transgender youth in a lawsuit filed Friday. The complaint comes after a month in which at least eight major hospitals and hospital systems - all in states where the care is allowed under state law - announced they were stopping or restricting the care. The latest announcement came Thursday from UI Health in Chicago. Trump 's administration announced in July that it was sending subpoenas to providers and focusing on investigating them for fraud. It later boasted in a news release that hospitals are halting treatments. The Democratic officials say Trump's policies are an attempt to impose a nationwide ban on the treatment for people under 19 - and that's unlawful because there's no federal statute that bans providing the care to minors. The suit was filed by attorneys general from 15 states and the District of Columbia, plus the governor of Pennsylvania, in U.S. District Court in Boston. "The federal government is running a cruel and targeted harassment campaign against providers who offer lawful, lifesaving care to children," New York Attorney General Letitia James said in a statement. Trump and others who oppose the care say that it makes permanent changes that people who receive it could come to regret - and maintain that it's being driven by questionable science. Since 2021, 28 states with Republican-controlled legislatures have adopted policies to ban or restrict gender-affirming care for minors. In June, the U.S. Supreme Court ruled that states have a right to enforce those laws. For families with transgender children, the state laws and medical center policy changes have sparked urgent scrambles for treatment. The medical centers are responding to political and legal pressure The Center for Transyouth Health and Development at Children's Hospital Los Angeles, the biggest public provider of gender-affirming care for children in teens in the U.S., closed in July. At least seven other major hospitals and health systems have made similar announcements, including Children's National in Washington D.C., UChicago Medicine and Yale New Haven Health . Kaiser Permanente, which operates in California and several other states, said it would pause gender-affirming surgeries for those under 19 as of the end of August, but would continue hormone therapy. Connecticut Children's Medical Center cited "an increasingly complex and evolving landscape" for winding down care. Other hospitals, including Penn State, had already made similar decisions since Trump returned to office in January. Alex Sheldon, executive director of GLMA, an organization that advocates for health care equity for LGBTQ+ people, said the health systems have pulled back the services for legal reasons, not medical ones. "Not once has a hospital said they are ending care because it is not medically sound," Sheldon said. Trump's administration has targeted the care in multiple ways Trump devoted a lot of attention to transgender people in his campaign last year as part of a growing pushback from conservatives as transgender people have gained visibility and acceptance on some fronts. Trump criticized gender-affirming care, transgender women in women's sports, and transgender women's use of women's facilities such as restrooms. On his inauguration day in January, Trump signed an executive order defining the sexes as only male and female for government purposes, setting the tone for a cascade of actions that affect transgender people. About a week later, Trump called to stop using federal money, including from Medicaid, for gender-affirming care for those under 19. About half of U.S. adults approve of Trump's handling of transgender issues, an AP-NORC poll found. But the American Medical Association says that gender is on a spectrum, and the group opposes policies that restrict access to gender-affirming health care. Gender-affirming care includes a range of medical and mental health services to support a person's gender identity, including when it's different from the sex they were assigned at birth. It includes counseling and treatment with medications that block puberty, and hormone therapy to produce physical changes, as well as surgery, which is rare for minors. In March, a judge paused enforcement of the ban on government spending for care. The court ruling didn't stop other federal government action In April, Attorney General Pam Bondi directed government investigators to focus on providers who continue to offer gender-affirming care for transgender youth. "Under my leadership, the Department of Justice will bring these practices to an end," she wrote. In May, the Department of Health and Human Services issued a report discouraging medical interventions for transgender youth and instead focusing solely on talk therapy. The report questions adolescents' capacity to consent to life-changing treatments that could result in future infertility. The administration has not said who wrote the report, which has been deeply criticized by LGBTQ+ advocates. In June, a Justice Department memo called for prioritizing civil investigations of those who provide the treatment. In July, Justice Department announced it had sent more than 20 subpoenas to doctors and clinics involved in gender-affirming care for youth, saying they were part of investigations of health care fraud, false statements and other possible wrongdoing. And in a statement last week, the White House celebrated decisions to end gender-affirming care, which it called a "barbaric, pseudoscientific practice" Families worry about accessing care Kirsten Salvatore 's 15-year-old child started hormone therapy late last year at Penn State Health. Salvatore said in an interview with The Associated Press before the lawsuit was announced that it was a major factor in reduced signs of anxiety and depression. Last month, the family received official notice from the health system that it would no longer offer the hormones for patients under 19 after July 31, though talk therapy can continue. Salvatore has been struggling to find a place that's not hours away from their Mechanicsburg, Pennsylvania, home that would provide the hormones and accept Medicaid coverage. "I'm walking around blind with no guidance, and whatever breadcrumbs I was given are to a dead-end alleyway," she said. The family has enough testosterone stockpiled to last until January. But if they can't find a new provider by then, Salvatore's child could risk detransitioning, she said.
Indian Express
a day ago
- Indian Express
Hepatitis A surges with monsoon: What tests to do, what vaccines to take and how to keep the virus at bay
When a 30-year-old woman walked into Dr Rommel Tickoo's clinic, one look at her yellowish eyes told him that she had a liver problem. Sure enough, when the internal medicine expert at Max Healthcare, Delhi, checked her liver enzymes, they were through the roof. Her enzyme levels stood at around 3,000 IU/L — the normal ranges are between 7 and 55 IU/L. She tested positive for hepatitis A, a viral infection usually transmitted through contaminated food and water. With several gastrointestinal infections and vector-borne diseases being common during the monsoon, getting the correct diagnosis may be a challenge. 'The typical symptoms, such as yellowing of skin and eyes that people associate with hepatitis, are not the first ones to appear. The yellowing happens at later stages of the disease, where there are high levels of accumulated bilirubin (a yellow pigment produced when the red blood cells break down, usually cleared out by the liver). A person should ideally go to a doctor before this happens,' says Dr Tickoo. Why a test matters The overlapping symptoms, which can be caused by other gastrointestinal infections, are the reason that doctors go in for tests to be sure. As Dr Suranjit Chatterjee, senior consultant of internal medicine at Indraprastha Apollo Hospital, Delhi, says, 'During this season, you would either see food and water-borne infections, vector-borne infections and some respiratory infections. Usually, patients coming in with symptoms such as loose motions, vomiting, loss of appetite have gastrointestinal diseases such as hepatitis A, E, gastroenteritis or typhoid. High fever, headache and body ache would usually be the symptoms in patients with vector-borne diseases such as dengue, malaria or chikungunya.' Dr Tickoo usually gets such patients tested for complete blood count, liver enzyme and C-reactive protein, the last indicative of the inflammation in the body. Then he prescribes tests for dengue, malaria, typhoid, and in some cases, especially concerning the women and elderly, he gets a urine culture to check for urinary tract infection. When to see a doctor People who get fever, nausea, vomiting or diarrhoea should go to a doctor if the symptoms seem to be worsening or do not seem to be improving after a couple of days. Dr Chatterjee advises that anyone who is immunocompromised — for example, if they are living with conditions such as heart diseases, liver disease, kidney disease, diabetes, cancers, HIV, or have undergone an organ transplantation — should go to their doctor sooner. 'One should also go to a doctor immediately if their symptoms are unmanageable, say if they are vomiting or getting loose motions more than 20 times a day,' he says. Do not pop pills at will Importantly, people with these symptoms should only take medicines such as paracetamol and those to prevent vomiting when at home. 'Other medicines such as Combiflam should be avoided. Pain medications such as diclofenac or mefenamic acid should also be avoided, especially when diseases like dengue are likely. These medicines are known to increase the risk of bleeding in patients with dengue. Antibiotics are a strict no-no. They are of no use in cases of viral infections such as hepatitis, can lead to growing antimicrobial resistance and, importantly, may also affect the results of certain tests we need to confirm our diagnosis,' says Dr Tickoo. While most people with hepatitis A get better within four to 16 weeks, some go on to develop serious complications such as liver failure and coma. 'It is, however, impossible to tell who will get the complications. So it is essential that everyone who has the hepatitis A infection takes rest and helps the body recover,' says Dr Ashwini Setya, senior consultant of gastroenterology at Medanta, Gurugram. What to eat during recovery While at home, patients should ensure that they drink plenty of fluids and eat healthy meals as per their appetite. 'It is a myth that people need to eat bland, boiled food. They should only eat as much as they feel like. Usually, people's appetite reduces significantly when they have a hepatitis infection. Force-feeding can lead to more nausea,' says Dr Setya. It is better to boil water and follow hand hygiene, according to Ritika Samaddar, regional head, dietetics and nutrition, Max Healthcare. 'During the recovery phase, liver cells are regenerating. So they need protein in the form of eggs, milk and paneer. They need good fat, so normal refined, olive and nut oils work, but in moderation. A teaspoon of ghee can be had too to whet the appetite. Carbs are equally important for regenerating liver cells. Have small, frequent meals,' she says. However, she warns that the diet discipline must be adhered to strictly for at least six months. 'Hepatitis A is a self-limiting infection. But sometimes there can be a relapse if you do not take care. Besides, you could be at risk of other strains of the hepatitis virus. A diet discipline is a must,' says Samaddar. She even suggests a strict preventive regime: 'Please drink only filtered and boiled water, even cook with it. Wash all your fruits and vegetables thoroughly. Do not eat raw or undercooked foods. Avoid street food, cut fruits and even ice drinks from the roadside or restaurants.' Take the preventive shot There are five hepatitis viruses that cause liver disease in humans. Hepatitis A and E are transmitted through contaminated food and water and usually do not lead to lasting liver damage. Hepatitis B, C and D, on the other hand, are usually transmitted by blood and can lead to chronic infections. At present, vaccines are available against hepatitis A and B. This may also reduce the risk of hepatitis D, which can only occur in people who have hepatitis B infection. While there is no vaccine for hepatitis C, there is an effective antiviral treatment. 'When it comes to water-borne hepatitis, any person who has had hepatitis A is immune for life, but hepatitis E can happen multiple times,' says Dr Setya. Hepatitis E infection in a pregnant woman can lead to abortion of a foetus and increase the risk of maternal mortality, he adds. So, who should take the hepatitis A vaccine? Doctors recommend it for children, students living in hostels, people who eat out often or those who are immunocompromised. Others may also take it to reduce the risk of an infection, but it is not necessary for everyone. (With inputs by Rinku Ghosh) Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government's management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country's space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University's Dart Centre. Dutt has a Bachelor's Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More
